Quick Answer
PLUS THERAPEUTICS, INC. reported Research And Development Expense of $8.38 million for the year ending 2025.
- PLUS THERAPEUTICS, INC. showed a decrease of -20.8% in Research And Development Expense from 2024 to 2025.
- This data is from PLUS THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $2.30 million | Q3 2010: $2.48 million | Q1 2011: $3.05 million | Q2 2011: $3.07 million | Q3 2011: $2.83 million | Q1 2012: $2.84 million | Q2 2012: $3.22 million | Q3 2012: $3.56 million | Q1 2013: $3.72 million | Q2 2013: $4.15 million | Q3 2013: $4.12 million | Q1 2014: $4.29 million | Q2 2014: $4.67 million | Q3 2014: $3.14 million | Q1 2015: $3.96 million | Q2 2015: $6.05 million | Q3 2015: $4.35 million | Q1 2016: $4.13 million | Q2 2016: $5.25 million | Q3 2016: $3.96 million | Q1 2017: $3.29 million | Q2 2017: $2.99 million | Q3 2017: $3.00 million | Q1 2018: $2.50 million | Q2 2018: $1.27 million | Q3 2018: $1.23 million | Q1 2019: $1.43 million | Q2 2019: $1.29 million | Q3 2019: $921.0 thousand | Q1 2020: $941.0 thousand | Q2 2020: $327.0 thousand | Q3 2020: $336.0 thousand | Q1 2021: $1.13 million | Q2 2021: $1.11 million | Q3 2021: $1.49 million | Q1 2022: $1.79 million | Q2 2022: $2.83 million | Q3 2022: $2.95 million | Q1 2023: $2.98 million | Q2 2023: $1.42 million | Q3 2023: $2.49 million | Q1 2024: $2.76 million | Q2 2024: $2.77 million | Q3 2024: $2.86 million | Q1 2025: $1.76 million | Q2 2025: $1.25 million | Q3 2025: $2.44 million.
- Over the full 16 years of available data (2009 to 2025), PLUS THERAPEUTICS, INC.'s Research And Development Expense has declined by 31.5%.
- Historical annual values: Fiscal year 2025: $8.38 million | Fiscal year 2024: $10.58 million | Fiscal year 2023: $9.69 million | Fiscal year 2022: $9.70 million | Fiscal year 2020: $2.70 million | Fiscal year 2019: $5.37 million | Fiscal year 2018: $5.52 million | Fiscal year 2017: $11.68 million | Fiscal year 2016: $16.20 million | Fiscal year 2015: $19.00 million | Fiscal year 2014: $15.11 million | Fiscal year 2013: $17.07 million | Fiscal year 2012: $13.63 million | Fiscal year 2011: $10.90 million | Fiscal year 2010: $9.69 million | Fiscal year 2009: $12.23 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: